Table of Contents Author Guidelines Submit a Manuscript
Behavioural Neurology
Volume 6, Issue 1, Pages 33-35

Transdermal Physostigmine—Absence of Effect on Topographic Brain Mapping

M. Y. Neufeld,1,3 F. Mawassi,1 A. Levy,2 T. A. Treves,1 and A. D. Korczyn1

1Department of Neurology, Tel-Aviv Sourasky Medical Center and Sackler School of Medicine, Israel
2Israel Institute for Biological Research, Ness Ziona, Israel
3IDepartment of Neurology, Tel-Aviv Sourasky Medical Center, 6 Weizmann Street, Tel-Aviv 64239, Israel

Received 1 March 1993; Accepted 16 March 1993

Copyright © 1993 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Nine patients with primary degenerative dementia (PDD) participated in an open trial of transdermal physostigmine (TPh). In order to evaluate the neurophysiologic effects of TPh, EEG data were recorded and compared at baseline and following 2 months of continuous treatment. There was no significant effect of TPh on EEG spectra in patients with PDD.